ViroCell Biologics adds former Charles River exec to its team
7 October 2024
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announces the appointment of Nicholas Ostrout, as vice president of corporate development and strategy.
Mr Ostrout brings a wealth of CGT commercial development and corporate strategy experience to ViroCell’s growing team, as the company moves to expand its network of strategic partners. He was most recently senior director of strategic development and partnerships at Charles River Laboratories (NYSE: CRL), where he was responsible for developing and executing business engagement and development strategies for the company’s CGT assets, across the entire Charles River portfolio.
Prior to this, Mr Ostrout worked at Lonza as senior director (global head) of commercial development, within Lonza’s (VTX: LONN) Personalized Medicine Business Unit. There, he served as head of the transactions team, securing access to promising technologies in the area of cell therapy manufacturing and development. Mr Ostrout Nicholas holds a PhD in immunology from the Case Western Reserve University, Cleveland, Ohio, and a Bachelor of Sciences degree from Denison University, Granville, Ohio.